Citations

Showing 10 of 108104 citations.

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
Campo, Elı́as , Jaffe, Elaine S. , Cook, James R. , Quintanilla‐Martínez, Leticia , Brousset, Pierre , Cerroni, Lorenzo , Dirnhofer, Stefan , Friedberg, Jonathan W. , King, Rebecca L., Miguel, Jesús F. San , Seymour, John F. , Advani, Ranjana H. , Ansell, Stephen M. , Au, Wing-Yan, Bergsagel, Leif, Cohen, Jeffrey I. , d’Amore, Francesco, Ghobrial, Irene M. , Kim, Won-Seog, Kumar, Shaji , LaCasce, Ann S. , Laurent, Camille , Lenz, Georg, Leonard, John P. , Link, Michael P., López‐Guillermo, Armando , Mateos, María‐Victoria , Melnick, Ari , Nakamura, Shigeo, Narbaitz, Marina, Pavlovsky, Astrid , Pro, Barbara, Sander, Birgitta , Smith, Sonali M. , Staudt, Louis M. , Thieblemont, Catherine, Tousseyn, Thomas , Wilson, Wyndham H., Yoshino, Tadashi, Dreyling, Martin , Winter, Jane N., Bergsagel, P. Leif , Dirnhofer, S , Bergsagel, P. Leif , Brousset, Pierre , Dogan, Ahmet , Feldman, Andrew L , Ghia, Paolo , Salles, Gilles A , San-Miguel, Jesus , Seymour, John F , Treon, Steven , Vose, Julie , Zucca, Emanuele , Barrionuevo, Carlos , Davies, Andrew , Falini, Brunangelo , Ghobrial, Irene M , Goodlad, John R , Gribben, John G. , Hsi, Eric D , Kahl, Brad S , Kumar, Shaji K , LaCasce, Ann Steward , Mateos, María-Victoria , Macintyre, Elizabeth , Melnick, Ari , Morschhauser, Franck , Pileri, Stefano , Piris, Miguel , Rajkumar, Vincent, Shipp, Margaret Ann , Smith, Sonali M , Zinzani, Pier Luigi , Dreyling, Martin , Scott, David W , Zelenetz, Andrew D , Jaffe, Elaine S , Campo, Elías , Advani, Ranjana H , Quintanilla-Martinez, Leticia , Swerdlow, Steven H. , Anderson, Kenneth C. , Leval, Laurence de , Doǧan, Ahmet , Feldman, Andrew L. , Fend, Falko , Gaulard, Philippe , Ghia, Paolo , Horwitz, Steven M. , Salles, Gilles , Treon, Steven P. , Vose, Julie M. , Zucca, Emanuele , Chan, Wing C., Davies, Andrew , Falini, Brunangelo , Hsi, Eric D. , Kahl, Brad S. , Kim, Won Seog , Lenz, Georg , Macintyre, Elizabeth , Morschhauser, Franck , Pileri, Stefano , Piris, Miguel Á. , Rajkumar, S. Vincent , Rosen, Steven T. , Sehn, Laurie H. , Thiéblemont, Catherine , Wilson, Wyndham H. , Yoshino, Tadashi, Zinzani, Pier Luigi , Scott, David W. , Winter, Jane N. , Zelenetz, Andrew D.

Mayo Clinic

Blood | June 2, 2022 | Volume: 140 | Issue: 11 | Pages: 1229-1253

10.1182/blood.2022015851 | PMID 35653592 Get It

Abstract Since the publication of the Revised European-American Classification of Lymphoid Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have been generated through iterative international efforts to achieve broad consensus among hematopathologists, geneticists, molecular scientists, and clinicians. Significant progress has recently been made in the characterization of malignancies of the immune system, with many new insights provided by genomic studies. They have led to this proposal. We have followed the same process that was successfully used for the third and fourth editions of the World Health Organization Classification of Hematologic Neoplasms. The definition, recommended studies, and criteria for the diagnosis of many entities have been extensively refined. Some categories considered provisional have now been upgraded to definite entities. Terminology for some diseases has been revised to adapt nomenclature to the current knowledge of their biology, but these modifications have been restricted to well-justified situations. Major findings from recent genomic studies have impacted the conceptual framework and diagnostic criteria for many disease entities. These changes will have an impact on optimal clinical management. The conclusions of this work are summarized in this report as the proposed International Consensus Classification of mature lymphoid, histiocytic, and dendritic cell tumors.
The aryl hydrocarbon receptor instructs the immunomodulatory profile of a subset of Clec4a4 + eosinophils unique to the small intestine
Wang, Wei-Le , Kasamatsu, Jun , Gilfillan, Susan , Luccia, Blanda Di , Panda, Santosh K., Kim, DoHyun , Desai, Pritesh , Bando, Jennifer K. , Yomogida, Kentaro , Hoshino, Hitomi , Fukushima, Mana, Jacobsen, Elizabeth A. , Dyken, Steven J. Van , Ruedl, Christiane , Gilfillan, Susan , Bando, Jennifer K , Van Dyken, Steven J , Ruedl, Christiane , Colonna, Marco , Jacobsen, Elizabeth A , Joshita, Satoru , Panda, Santosh K., Huang, Stanley Ching‐Cheng , Cella, Marina , Colonna, Marco

Mayo Clinic

Proceedings of the National Academy of Sciences | June 2, 2022 | Volume: 119 | Issue: 23 | Pages: No page available

10.1073/pnas.2204557119 | PMID 35653568 Get It

Significance Eosinophils contribute to type 2 immunity against helminths and allergens. The small intestine harbors eosinophils with incompletely understood pathophysiological roles. Here, we show that intestinal eosinophils include two subsets. One expresses the inhibitory receptor Clec4a4 and the inhibitory ligand PD-L1 and is unique to the small intestine; the other manifests a proinflammatory phenotype. Both subsets are blood derived. Remarkably, Clec4a4 + eosinophils were instructed by the aryl hydrocarbon receptor (AHR), a ligand-activated transcription factor that imprints many gut immune cells. Selective AHR deletion in eosinophils depleted Clec4a4 + eosinophils, augmented innate lymphocytes producing type 2 cytokines, and enhanced helminth clearance. We conclude that Clec4a4 + eosinophils have immunomodulatory functions, which could be harnessed for the therapy of food allergies and eosinophilic gastrointestinal disorders.
Left atrial appendage emptying velocity as a predictor of recurrence of atrial fibrillation post‐ablation
Ezzeddine, Fatima M. , DeSimone, Christopher V. , DeSimone, Christopher V , Ezzeddine, Fatima

Mayo Clinic

Journal of Cardiovascular Electrophysiology | June 2, 2022 | Volume: 33 | Issue: 8 | Pages: 1712-1713

10.1111/jce.15583 | PMID 35652824 Get It

Consecutive Transcutaneous and Epidural Spinal Cord Neuromodulation to Restore Complete Paralysis
Mukhametova, Elvira , Militskova, Alena , Biktimirov, Artur , Харин, Никита , Baltina, Tatyana , Семенова, Е. В. , Sachenkov, Oskar A. , Lavrov, Igor

Mayo Clinic

No container title available | June 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1671077/v1 Get It

Abstract In this study the effect of transcutaneous (tSCS) and epidural electrical spinal cord stimulation (EES) to facilitate volitional movements, balance, and non-motor functions was consecutively tested in two subjects with motor complete spinal cord injury (SCI). We hypothesized that tSCS and EES have different but complimentary effects on restoration after SCI. In both subjects tSCS demonstrated minimal improvement in volitional movements critical to initiate tSCS-enabled rehabilitation. Compared to tSCS, following EES demonstrated immediate restoration of volitional movements, while tSCS was more effective in improving balance. Continuous improvement in non-motor functions was found during tSCS-enabled and then EES-enabled rehabilitation. These results show significant difference in effect of tSCS and EES on recovery of neurologic functions and demonstrate advantages of consecutive tSCS and EES therapy of SCI. Proposed approach will help to select responsive to neuromodulation subjects and early initiate therapy, particularly for motor complete SCI with minimal effect from conventional rehabilitation.
Intravenous Bisphosphonate Therapy as a Rescue Analgesic in Refractory Fibrous Dysplasia
Hatcher, LeRanna , Henry, Nicole, Hooten, W. Michael , D’Souza, Ryan S. , D'Souza, Ryan S , Henry, Nicole

Mayo Clinic

Pain Medicine | June 2, 2022 | Volume: 23 | Issue: 12 | Pages: 2085-2089

10.1093/pm/pnac090 | PMID 35652736 Get It

Sex-Specific Physiological Responses to Ultramarathon
Tiller, Nicholas B. , Wheatley, Courtney M. , Fermoyle, Caitlin C. , Robach, Paul , Ziegler, Briana, Gavet, Alice , Schwartz, Jesse C., Constantini, Keren , Murdock, Robert, Johnson, Bruce D. , Stewart, Glenn M. , Taylor, Bryan J.

Mayo Clinic

Medicine & Science in Sports & Exercise | June 2, 2022 | Volume: 54 | Issue: 10 | Pages: 1647-1656

10.1249/mss.0000000000002962 | PMID 35653262 Get It

ABSTRACT Purpose Despite a growing body of literature on the physiological responses to ultramarathon, there is a paucity of data in females. This study assessed the female physiological response to ultramarathon and compared the frequency of perturbations to a group of race- and time-matched males. Methods Data were collected from 53 contestants of an ultramarathon trail race at the Ultra-Trail du Mont-Blanc (UTMB®) in 2018/19. Before and within 2 h of the finish, participants underwent physiological assessments, including blood sampling for biomarkers (creatine kinase–MB isoenzyme [CK-MB], cardiac troponin I [cTnI], brain natriuretic peptide [BNP], and creatinine [Cr]), pulmonary function testing (spirometry, exhaled NO, diffusing capacities, and mouth pressures), and transthoracic ultrasound (lung comet tails, cardiac function). Data from eight female finishers (age = 36.6 ± 6.9 yr; finish time = 30:57 ± 11:36 h:min) were compared with a group of eight time-matched males (age = 40.3 ± 8.3 yr; finish time = 30:46 ± 10:32 h:min). Results Females exhibited significant pre- to postrace increases in BNP (25.8 ± 14.6 vs 140.9 ± 102.7 pg·mL −1 ; P = 0.007) and CK-MB (3.3 ± 2.4 vs 74.6 ± 49.6 IU·L −1 ; P = 0.005), whereas males exhibited significant pre- to postrace increases in BNP (26.6 ± 17.5 vs 96.4 ± 51.9 pg·mL −1 ; P = 0.002), CK-MB (7.2 ± 3.9 vs 108.8 ± 37.4 IU·L −1 ; P = 0.002), and Cr (1.06 ± 0.19 vs 1.23 ± 0.24 mg·dL −1 ; P = 0.028). Lung function declined in both groups, but males exhibited additional reductions in lung diffusing capacities (DL CO = 34.4 ± 5.7 vs 29.2 ± 6.9 mL⋅min −1 ⋅mm Hg −1 , P = 0.004; DL NO = 179.1 ± 26.2 vs 152.8 ± 33.4 mL⋅min −1 ⋅mm Hg −1 , P = 0.002) and pulmonary capillary blood volumes (77.4 ± 16.7 vs 57.3 ± 16.1 mL; P = 0.002). Males, but not females, exhibited evidence of mild postrace pulmonary edema. Pooled effect sizes for within-group pre- to postrace changes, for all variables, were generally larger in males versus females ( d = 0.86 vs 0.63). Conclusions Ultramarathon negatively affects a range of physiological functions but generally evokes more frequent perturbations, with larger effect sizes, in males compared to females with similar race performances.
High prevalence of fluoroquinolone‐resistant UTI among US emergency department patients diagnosed with urinary tract infection, 2018–2020
Faine, Brett , Vakkalanka, J. Priyanka , Gross, Alan E. , Brown, Caitlin S. , Harding, Stephanie J. , Slocum, Giles W. , Zimmerman, David E. , Zepeski, Anne , Rewitzer, Stacey , Howington, Gavin T. , Campbell, Matthew J. , Dawson, Jordan, Treu, Cierra N. , Nelson, Lucas , Jones, Mandy , Flack, Tara , Porter, Blake , Sarangarm, Preeyaporn , Mattson, Alicia E , Bailey, Abby M. , Kelly, Gregory , Talan, David A. , Faine, Brett A , Gross, Alan , Zimmerman, David , Zepeski, Anne , Campbell, Matt , Treu, Cierra N , Talan, David A , Vakkalanka, Priyanka , Rech, Megan A. , Jones, Mandy

Mayo Clinic

Academic Emergency Medicine | June 2, 2022 | Volume: 29 | Issue: 9 | Pages: 1096-1105

10.1111/acem.14545 | PMID 35652493 Get It

AbstractBackgroundUropathogen resistance, fluoroquinolone‐resistance (FQR), and extended spectrum beta‐lactamase (ESBL), has been observed to be emerging worldwide with prevalences above recommended thresholds for routine empirical treatment. The primary aim of our study was to determine the prevalence of FQR from a geographically diverse sample of United States emergency departments (EDs).MethodsWe conducted a multi‐center, observational cohort study using a network of 15 geographically diverse US EDs. All patients ≥18 years of age with the primary or secondary diagnosis of urinary tract infection (UTI) in the ED identified using International Classification of Diseases (ICD‐10) diagnosis code of cystitis, pyelonephritis, or UTI from 2018 to 2020 were included. We calculated descriptive statistics for uropathogens and susceptibilities. Logistic regression analysis was used to identify antimicrobial resistance risk factors associated with FQR Escherichia coli.ResultsAmong 3779 patients who met inclusion criteria, median age was 62.9 years (interquartile range [IQR]: 41–77.6) and 76.3% were female. The most common diagnoses were complicated (41.2%) and uncomplicated cystitis (40.3%). E. coli was the most common pathogen (63.2%), followed by Klebsiella pneumoniae (13.2%) and Enterococcus species (5.8%). Across all sites, overall E. coli FQ‐resistance prevalence was 22.1%, ranging from 10.5 to 29.7% by site. The prevalence of ESBL‐producing uropathogen was 7.4%, ranging from 3.6% to 11.6% by site. Previous IV or oral antimicrobial use in the past 90‐days and history of a multi‐drug resistant pathogen were associated with FQ‐resistant E. coli (odds ratio [OR] 2.68, 95% confidence interval [CI]: 2.04–3.51, and OR 6.93, 95% CI: 4.95–9.70, respectively). Of the patients who had FQ‐resistant E. coli or an ESBL‐producing uropathogen isolated, 116 (37.1%) and 61 (36.7%) did not have any documented risk factors for resistance.ConclusionFQ‐resistant E. coli is widely prevalent across US sites highlighting the need for ongoing monitoring of antimicrobial resistance and, at some locations, modification of empirical treatments.
Underreporting and Underrepresentation of Race and Ethnicity in Head and Neck Cancer Trials, 2010-2020
Sauer, Adam , Daher, Ghazal S. , Lohse, Christine M. , Glasgow, Amy E. , Douse, Dontre’ M. , Moore, Eric J. , Ighodaro, Eseosa T. , Abel, Kathryn M. Van , Glasgow, Amy E. , Sauer, Adam B, Van Abel, Kathryn M , Glasgow, Amy E , Habermann, Elizabeth B. , Yin, Linda X.

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | June 2, 2022 | Volume: 148 | Issue: 7 | Pages: 662

10.1001/jamaoto.2022.1028 | PMID 35653143 Get It

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
Davies, Faith E. , Pawlyn, Charlotte , Usmani, Saad Z. , Miguel, Jesús F. San , Boyle, Eileen M. , Corre, Jill , Auclair, Daniel , Cho, Hearn Jay , Sonneveld, Pieter , Stewart, A. Keith , Bergsagel, P. Leif , Kaiser, Martin , Morgan, Kathryn E., Ghobrial, Irene M. , Orlowski, Robert Z. , Caers, Joseph, Chari, Ajai , Walker, Brian A. , Kumar, Shaji , Costa, Luciano J. , Bergsagel, P. Leif , San-Miguel, Jesus , Boyle, Eileen M , Corre, Jill , Cho, Hearn Jay , Kaiser, Martin F , Keats, Jonathan J , Mikhael, Joseph R , Orlowski, Robert Z. , Landgren, C Ola , Gay, Francesca , Chng, Wee Joo , Chari, Ajai , Walker, Brian A , Kumar, Shaji K , Costa, Luciano J , Anderson, Kenneth C , Morgan, Gareth J , Davies, Faith E , Ghobrial, Irene M , Pawlyn, Charlotte , Usmani, Saad , Einsele, Hermann , Lonial, Sagar , Weisel, Katja C , Keats, Jonathan J. , Mıkhael, Joseph , Landgren, Ola , Gay, Francesca , Chng, Wee Joo , Anderson, Kenneth C. , Morgan, Gareth J.

Mayo Clinic

Blood Cancer Discovery | June 2, 2022 | Volume: 3 | Issue: 4 | Pages: 273-284

10.1158/2643-3230.bcd-21-0205 | PMID 35653112 Get It

Summary: The multiple myeloma treatment landscape has changed dramatically. This change, paralleled by an increase in scientific knowledge, has resulted in significant improvement in survival. However, heterogeneity remains in clinical outcomes, with a proportion of patients not benefiting from current approaches and continuing to have a poor prognosis. A significant proportion of the variability in outcome can be predicted on the basis of clinical and biochemical parameters and tumor-acquired genetic variants, allowing for risk stratification and a more personalized approach to therapy. This article discusses the principles that can enable the rational and effective development of therapeutic approaches for high-risk multiple myeloma.
Roles of Notch Signaling in the Tumor Microenvironment
D’Assoro, Antonino B. , Leon‐Ferre, Roberto A. , Braune, Eike-Benjamin, Lendahl, Urban

Mayo Clinic

International Journal of Molecular Sciences | June 2, 2022 | Volume: 23 | Issue: 11 | Pages: 6241

10.3390/ijms23116241 | PMID 35682918 Get It

The Notch signaling pathway is an architecturally simple signaling mechanism, well known for its role in cell fate regulation during organ development and in tissue homeostasis. In keeping with its importance for normal development, dysregulation of Notch signaling is increasingly associated with different types of tumors, and proteins in the Notch signaling pathway can act as oncogenes or tumor suppressors, depending on the cellular context and tumor type. In addition to a role as a driver of tumor initiation and progression in the tumor cells carrying oncogenic mutations, it is an emerging realization that Notch signaling also plays a role in non-mutated cells in the tumor microenvironment. In this review, we discuss how aberrant Notch signaling can affect three types of cells in the tumor stroma—cancer-associated fibroblasts, immune cells and vascular cells—and how this influences their interactions with the tumor cells. Insights into the roles of Notch in cells of the tumor environment and the impact on tumor-stroma interactions will lead to a deeper understanding of Notch signaling in cancer and inspire new strategies for Notch-based tumor therapy.